Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation
Sponsor: Roche Pharma AG
A PHASE2 clinical study on Non-small Cell Lung Cancer Stage III, this trial is ongoing. The trial is conducted by Roche Pharma AG and has accumulated 7 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Roche Pharma AG
- Tianjin Medical University Cancer Institute and Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China , Qingdao, China , Shanghai, China , Shenyang, China , Shijiazhuang, China and 3 more locations